JPRN-jRCT1091220003已完成2 期
Phase2 Study of Glivec (imatinib mesylate, formerly known as STI571) in Patients with Relapsed or Refractory Sarcomas with c-kit or PDGFR Expression - CSTI571BJP04
Office of Imatinib phase 2 study0 个研究点目标入组 40 人开始时间: 2005年12月28日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1) Histologically confirmed metastatic or unresectable locally advanced sarcomas (excluding gastrointestinal stromal tumor) Eligible subtypes: Ewing's sarcoma / Primitive neuroectodermal tumor(PNET); Synovial sarcoma; Neuroblastoma; Desmoplastic small round cell tumor; Leiomyosarcoma; Rabdomyosarcoma; Liposarcoma; Fibrosarcoma; Angiosarcoma; Malignant fibrous histiocytoma; Malignant peripheral nerve sheath tumor; Osteosarcom; Alveolar soft part sarcoma; Epitheloid sarcom; Clear cell sarcoma
- •2) c-kit positive tumor(CD117 expression on immunohistochmial staining)
- •3) Tumor tissue blocks must be available
- •4) Relapsed or refractory to comventional chemotherapy
- •5) At least 1 measurable lesion: At least 20mm by conventional techniques or at least 10mm by spiral CT scan
- •6) Chemotherapy: at least 4 weeks since prior chemotherapy and no concurrent therapy
- •7) Age: 12<= and <75
- •8) Written informed consent
排除标准
- •1) uncontrolable or active infection
- •2) pregnacy or lactation
- •3) brain metastasis with clinical symptom
研究者
相似试验
已完成
2 期
Phase2 Study of Glivec (imatinib mesylate, formerly known as STI571) in Patients with Relapsed or Refractory Sarcomas with c-kit or PDGFR ExpressioSarcoma with c-kit or PDGFR expression by immunohistochemistryJPRN-C000000073Office of Imatinib phase2 study40
已完成
2 期
Glivec plus chemotherapy in blast-phase CML and Ph+ ABlast-Phase Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCancer - Leukaemia - Acute leukaemiaCancer - Leukaemia - Chronic leukaemiaACTRN12605000072617Australasian Leukaemia and Lymphoma Group41
进行中（未招募）
不适用
Phase II study of Glivec (imatinib mesylate) in patients with advanced neuroblastoma - NDHigh risk NeuroblastomaMedDRA version: 6.1Level: PTClassification code 10029260EUCTR2005-005778-63-ITISTITUTO GIANNINA GASLINI
进行中（未招募）
1 期
Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF rearrangement i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)EUCTR2004-002538-20-GBEuropean Organisation for Research and Treatment of Cancer44
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage IV Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00041340National Cancer Institute (NCI)37